In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chong Kun Dang Pharmaceutical Corp.

http://www.ckdpharm.com/en/home

Latest From Chong Kun Dang Pharmaceutical Corp.

Biopharma Market Fuels South Korean Growth Engine

South Korea is the tenth largest economy in the world with a population of 51.3 million. Alongside fast growth of the region’s technology-driven economy, its pharma industry has been expanding significantly too. 

Asia Pacific South Korea

Bio Korea: R&D Strategies To Tackle Global COVID-19 Market

The Bio Korea meeting included a discussion around the challenges faced by Korean developers of COVID-19 therapies and vaccines and how they should approach the global market. Cooperation and production technology will be key.

South Korea Coronavirus COVID-19

Korean Pharmas Race To Globalize But Tacks Vary

Although South Korean pharma firms are largely sailing toward the common goal of globalization, they have different strategies to reach their goals. Scrip takes a look at the variety of paths being pursued.

South Korea Business Strategies

Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader

After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.

Coronavirus COVID-19 BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register